MJFF Announces $2-Million Funding Commitment to Drive Development of Parkinson's Disease Biomarker Pipeline
Facebook
Facebook
Twitter
Twitter
LinkedIn
LinkedIn
Email
Email
0 Comments
Comments
“Lack of biomarkers is a major impediment to the development of disease-modifying treatments for Parkinson’s disease, in large part because outcomes of clinical trials are extremely difficult to measure,” said Katie Hood, CEO. “While considered a high-risk pursuit by many, The Michael J. Fox Foundation will continue to push biomarker research because development of PD biomarkers would be a major tipping point for the field, greatly accelerating the development of transformative new therapies.”
0 Comments
View Comments
- Companies:
- Michael J. Fox Foundation
Related Content
Comments